Q&A: Roche responds to the community
Roche has responded to our request by answering questions from the community regarding their recent decision to not initiate any new trials of rugonersen (RO7248824) in Angelman syndrome.
Questions & Answers from Roche
Please consider joining the ASF/FAST hosted webinar on July 7 at 12pm ET with Dr. Elizabeth Berry-Kravis, a principal investigator for the Roche (Tangelo) program.